Cargando…

The clinical evidence for postbiotics as microbial therapeutics

An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concern...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosca, Alexis, Abreu Y Abreu, Ana Teresa, Gwee, Kok Ann, Ianiro, Gianluca, Tack, Jan, Nguyen, Thi Viet Ha, Hill, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542959/
https://www.ncbi.nlm.nih.gov/pubmed/36184735
http://dx.doi.org/10.1080/19490976.2022.2117508
_version_ 1784804264807235584
author Mosca, Alexis
Abreu Y Abreu, Ana Teresa
Gwee, Kok Ann
Ianiro, Gianluca
Tack, Jan
Nguyen, Thi Viet Ha
Hill, Colin
author_facet Mosca, Alexis
Abreu Y Abreu, Ana Teresa
Gwee, Kok Ann
Ianiro, Gianluca
Tack, Jan
Nguyen, Thi Viet Ha
Hill, Colin
author_sort Mosca, Alexis
collection PubMed
description An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy.
format Online
Article
Text
id pubmed-9542959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-95429592022-10-08 The clinical evidence for postbiotics as microbial therapeutics Mosca, Alexis Abreu Y Abreu, Ana Teresa Gwee, Kok Ann Ianiro, Gianluca Tack, Jan Nguyen, Thi Viet Ha Hill, Colin Gut Microbes Review An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy. Taylor & Francis 2022-10-02 /pmc/articles/PMC9542959/ /pubmed/36184735 http://dx.doi.org/10.1080/19490976.2022.2117508 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Mosca, Alexis
Abreu Y Abreu, Ana Teresa
Gwee, Kok Ann
Ianiro, Gianluca
Tack, Jan
Nguyen, Thi Viet Ha
Hill, Colin
The clinical evidence for postbiotics as microbial therapeutics
title The clinical evidence for postbiotics as microbial therapeutics
title_full The clinical evidence for postbiotics as microbial therapeutics
title_fullStr The clinical evidence for postbiotics as microbial therapeutics
title_full_unstemmed The clinical evidence for postbiotics as microbial therapeutics
title_short The clinical evidence for postbiotics as microbial therapeutics
title_sort clinical evidence for postbiotics as microbial therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542959/
https://www.ncbi.nlm.nih.gov/pubmed/36184735
http://dx.doi.org/10.1080/19490976.2022.2117508
work_keys_str_mv AT moscaalexis theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT abreuyabreuanateresa theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT gweekokann theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT ianirogianluca theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT tackjan theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT nguyenthivietha theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT hillcolin theclinicalevidenceforpostbioticsasmicrobialtherapeutics
AT moscaalexis clinicalevidenceforpostbioticsasmicrobialtherapeutics
AT abreuyabreuanateresa clinicalevidenceforpostbioticsasmicrobialtherapeutics
AT gweekokann clinicalevidenceforpostbioticsasmicrobialtherapeutics
AT ianirogianluca clinicalevidenceforpostbioticsasmicrobialtherapeutics
AT tackjan clinicalevidenceforpostbioticsasmicrobialtherapeutics
AT nguyenthivietha clinicalevidenceforpostbioticsasmicrobialtherapeutics
AT hillcolin clinicalevidenceforpostbioticsasmicrobialtherapeutics